Peter Blume-Jensen, Acrivon Therapeutics CEO

Acrivon bags a megaround to ad­vance an old Eli Lil­ly pro­gram, 5 months af­ter launch. Is an IPO far be­hind?

Not five months af­ter launch­ing with an old Eli Lil­ly as­set, Acrivon Ther­a­peu­tics is al­ready up­ping the ante.

The Cam­bridge, MA-based biotech pulled in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.